$CNAT new volume breakout candles Nasdaq $3.15
Post# of 63696
Posted On: 04/06/2016 5:07:15 PM
$CNAT new volume breakout candles
Nasdaq $3.15
Website
Shares Outstanding: 20.81M
Float: 14.69M
% Held by Insiders: 26.83%
% Held by Institutions: 34.40%
Shares Short (as of Mar 15, 2016): 814.16K
Short Ratio (as of Mar 15, 2016): 6.17
Short % of Float (as of Mar 15, 2016): 5.59%
Shares Short (prior month): 877.77K
Headlines
Company Profile-Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
Nasdaq $3.15
Website
Shares Outstanding: 20.81M
Float: 14.69M
% Held by Insiders: 26.83%
% Held by Institutions: 34.40%
Shares Short (as of Mar 15, 2016): 814.16K
Short Ratio (as of Mar 15, 2016): 6.17
Short % of Float (as of Mar 15, 2016): 5.59%
Shares Short (prior month): 877.77K
Headlines
Company Profile-Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
(0)
(0)Scroll down for more posts ▼